Southern Company vs Vertex Pharmaceuticals Incorporated — how do they compare? Southern Company trades at $88.39 (market cap $102.37B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Southern Company pays a 3.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SO | VRTX | |
|---|---|---|
Market Cap | $102.37B | $134.06B |
Sector | Utilities | Health |
52-Week High | $99.72 | $557.96 |
52-Week Low | $84.08 | $376.62 |
Enterprise Value | $176.47B | $128.18B |
Dividend Yield | 3.42% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Trailing returns across standard periods
Latest headlines on both assets
Southern Company is a U.S. energy company with electric and gas utility businesses. Its power generation portfolio includes natural gas, nuclear, renewable, and other energy sources.
Read more on SO →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →